Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1246564.RAajd5lmWgQLAdNGCfOOxpfJAsy4Vlm9w4pYG5qMQhJs8130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1246564.RAajd5lmWgQLAdNGCfOOxpfJAsy4Vlm9w4pYG5qMQhJs8130_assertion type Assertion NP1246564.RAajd5lmWgQLAdNGCfOOxpfJAsy4Vlm9w4pYG5qMQhJs8130_head.
- NP1246564.RAajd5lmWgQLAdNGCfOOxpfJAsy4Vlm9w4pYG5qMQhJs8130_assertion description "[Multivariate analysis revealed that elevated serum HER2 ECD was a significant independent prognostic factor for worse distant-metastasis-free survival [DMFS; hazard ratio (HR) = 2.50, 95% confidence interval (CI) = 1.5-4.3, P = 0.001] and breast-cancer-specific survival (BCSS; HR = 2.0, 95% CI = 1.1-3.8, P = 0.036), which were much stronger in patients with tissue HER2-positive tumors (DMFS: HR = 3.8, 95% CI = 2.0-7.0, P < 0.001; BCSS: HR = 2.6, 95% CI = 1.2-5.3, P = 0.012).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1246564.RAajd5lmWgQLAdNGCfOOxpfJAsy4Vlm9w4pYG5qMQhJs8130_provenance.
- NP1246564.RAajd5lmWgQLAdNGCfOOxpfJAsy4Vlm9w4pYG5qMQhJs8130_assertion evidence source_evidence_literature NP1246564.RAajd5lmWgQLAdNGCfOOxpfJAsy4Vlm9w4pYG5qMQhJs8130_provenance.
- NP1246564.RAajd5lmWgQLAdNGCfOOxpfJAsy4Vlm9w4pYG5qMQhJs8130_assertion SIO_000772 25491647 NP1246564.RAajd5lmWgQLAdNGCfOOxpfJAsy4Vlm9w4pYG5qMQhJs8130_provenance.
- NP1246564.RAajd5lmWgQLAdNGCfOOxpfJAsy4Vlm9w4pYG5qMQhJs8130_assertion wasDerivedFrom befree-2016 NP1246564.RAajd5lmWgQLAdNGCfOOxpfJAsy4Vlm9w4pYG5qMQhJs8130_provenance.
- NP1246564.RAajd5lmWgQLAdNGCfOOxpfJAsy4Vlm9w4pYG5qMQhJs8130_assertion wasGeneratedBy ECO_0000203 NP1246564.RAajd5lmWgQLAdNGCfOOxpfJAsy4Vlm9w4pYG5qMQhJs8130_provenance.